Ovarian cancer
Not recruitingStudy of Olaparib, Durvalumab and UV1 combination as maintenance treatment for patients with recurrent ovarian cancer who do not have BRCA mutations
Study of Olaparib, Durvalumab and UV1 combination as maintenance treatment for patients with recurrent ovarian cancer who do not have BRCA mutations
- Disease:Ovarian cancer
- Substances:AlrefimotideDurvalumab+3
Belgium- Participants:18–64 years · 65+ years
- Substances:Alrefimotide
- Sponsor:Nordic Society Of Gynaecological Oncology Clinical Trial Unit












